Do people with disabilities experience

- disparities in cancer care?
- 3 A systematic review
- 5 Irene Tosetti¹¶*, Hannah Kuper²¶
- 7 M.Sc. Public Health, London School of Hygiene & Tropical Medicine, London,
- 8 United Kingdom

4

6

10

- 9 https://orcid.org/0000-0001-5800-9153
- 11 ² International Centre for Evidence in Disability, London School of Hygiene &
- 12 Tropical Medicine, London, United Kingdom
- 13 https://orcid.org/0000-0002-8952-0023
- 15 * Corresponding Author
- 16 E-mail: lonit5@student.london.ac.uk

Abstract

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

Background: Over 1.3 billion people, or 16% of the world's population, live with some form of disability. Recent studies have reported that people with disabilities (PwD) might not be receiving state-of-the-art treatment for cancer as their non-disabled peers; our objective was to systematically review this topic. Methods: A systematic review was undertaken to compare cancer outcomes and quality of cancer care between adults with and without disabilities (NIHR Prospero register ID number: CRD42022281506). A search of the literature was performed in July 2022 across five databases: EMBASE, Medline, Cochrane Library, Web of Science and CINAHL databases. Peer-reviewed quantitative research articles, published in English from 2000 to 2022, with interventional or observational study designs, comparing cancer outcomes between a sample of adult patients with disabilities and a sample without disabilities were included. Studies focused on cancer screening and not treatment were excluded, as well as editorials, commentaries, opinion papers, reviews, case reports, case series under 10 patients and conference abstracts Studies were evaluated by one reviewer for risk of bias based on a set of criteria according to the SIGN 50 guidelines. A narrative synthesis was conducted according to the Cochrane SWiM guidelines, with tables summarizing study characteristics and outcomes. This research received no external funding. Results: Thirty-one studies were included in the systematic review. Compared to people without disabilities, PwD had worse cancer outcomes, in terms of poorer survival and higher overall and cancer-specific mortality. There was also evidence that PwD received poorer quality cancer care, including: lower access to state-of-the-

art care or curative-intent therapies, treatment delays, undertreatment or excessively invasive treatment, worse access to in-hospital services, less specialist healthcare utilization, less access to pain medications and inadequate end-of-life quality of care. Discussion: Limitations of this work include the exclusion of qualitative research, no assessment of publication bias, selection performed by only one reviewer, results from high-income countries only, no meta-analysis and a high risk of bias in 15% of included studies. In spite of these limitations, our results show that PwD often experience severe disparities in cancer care with less guideline-consistent care and higher mortality than people without disabilities. These findings raise urgent questions about how to ensure equitable care for PwD; in order to prevent avoidable morbidity and mortality, cancer care programs need to be evaluated and urgently improved, with specific training of clinical staff, more disability inclusive research, better communication and shared decision-making with patients and elimination of physical, social and cultural barriers.

Introduction

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

Cancer is a leading cause of death worldwide, resulting in nearly ten million deaths in 2020 according to WHO data.(1) In spite of this enormous burden of disease, latestage presentation and lack of diagnosis and treatment remain common, leading to much higher mortality rates.(2) Each cancer type requires a different treatment regimen, so a correct diagnosis is essential to receiving the best treatment and reducing mortality.(1-3)(1) Good quality of care can also improve quality of life (e.g. through pain management), even when cure is no longer possible. Access to appropriate treatment is therefore of crucial importance, but inequalities in access have been observed for several groups, including PwD.(4-10)Over 1.3 billion people, or 16% of the world's population, live with some form of disability, according to the 2022 World Report on Disability. (11) This figure is expected to grow further in the coming decades, as the population ages and chronic health conditions increase globally. On average, PwD are more likely to experience poor health, because of their underlying health condition/impairment and their socioeconomically excluded position in society. (14-15) They also face a range of barriers to accessing care, including long waiting times, high costs, ableist discrimination by health professionals, inaccessible buildings, inconvenient locations, and lack of communication among different parts of the healthcare team. (12) As a consequence, unmet healthcare needs are greater for PwD, contributing towards poorer health and higher mortality. (11) This general pattern of disability-related healthcare exclusion is reflected in known disparities in the use of cancer prevention services, as PwD have lower cancer screening rates than those without disabilities. (13–18) This gap may also exist with respect to cancer care, as several studies have

recently reported that patients with disabilities might not be receiving state-of-the-art treatment standards for their cancers. (19–23)Furthermore, several studies suggest that cancer may be diagnosed at a later stage in patients with disabilities, and that they experience treatment disparities resulting in higher cancer-specific mortality rates. (24,25) A recent meta-analysis from the USA showed that women with disabilities have 0.78 (95% CI: 0.72-0.84) lower odds of attending breast cancer screening and have 0.63 (95% CI: 0.45-0.88) lower odds of attending cervical cancer screening, compared to women without disabilities. A recent study from Taiwan reported that the probability of receiving colorectal cancer screening in people in the four categories of disability (intellectual and developmental disability, dementia, multiple disabilities, and moving functional limitation; OR = 0.53, 0.55, 0.62 and 0.81, respectively) was significantly lower than that in the general population. (25,26)Two recent scoping reviews found that patients with intellectual disabilities may be at risk of experiencing inequities at various points during cancer clinical pathways, which as a consequence could have an impact on their overall and cancer-specific mortality and quality of life; it is thus of the outmost importance to identify and address these disparities. (24,35) Consequently, the aim of this study is to conduct a systematic literature review to compare cancer outcomes and quality of cancer care between adults with and without disabilities.

Materials and methods

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

A systematic review of the literature was conducted describing differences in cancerrelated care between patients with and without disabilities, according to the PRISMA reporting guidelines; the study was recorded on the NIHR Prospero register of systematic reviews with ID number CRD42022281506. (27, 28)

Search Strategy

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

We used a systematic literature review to achieve our aim and objectives. The review was performed on July 1st 2022, across 5 databases: EMBASE, Medline, Cochrane Library, Web of Science and CINAHL databases. We included search terms on: disability (physical, sensory, psychological, communication and/or cognitive disability; measured clinically or through self-report); and cancer treatment (surgery, radiotherapy, chemotherapy, palliative care for any type of cancer), limited to the past 22 years (2000-June 2022), and to English language because of resource challenges with respect to costs, time, and expertise in non-English languages. The full search strategy can be found in the supporting information S1 file. Eligible studies included quantitative studies (observational or interventional), conducted in adults aged 18+, allowing comparison of cancer outcomes between PwD (of any type) and those without disabilities. The disability definition had to be in agreement with the International Classification of Functioning, Disability and Health (ICF) framework (i.e. including impairment, activity limitations or participation restriction due to an underlying health condition in interaction with personal and environmental barriers).(29) Studies had to include one or more measures of outcomes along the cancer clinical pathway of diagnosis, treatment, and follow-up or end of-life care. Eligible outcomes were overall mortality after cancer diagnosis, cancer-related mortality, survival, access to state-of-the-art treatment (defined as intent-to-cure treatment when feasible or guideline-consistent stage-appropriate treatment), type of treatment received (medical vs surgical vs radiation vs. hormonal), invasiveness of treatment, delay of treatment, specialist care utilization,

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

access to pain control prescription and end-of-life hospital use for palliative care. Studies focused on screening for cancer were not eligible, as this question was recently reviewed(33-36) There were no geographic restrictions. Types of study excluded were editorials, commentaries, opinion papers, reviews, case reports, case series under 10 patients and conference abstracts. Studies with patients under age 18 in a pediatric setting, studies without a measure of disability, studies that did not include a sample of patients with disabilities and a sample of patients without disabilities and studies without outcome measures for cancer care were also excluded. According to these criteria, studies with ineligible design, comparator, population, outcomes, intervention or setting were excluded. (Figure 1) **Study selection** All studies identified through the searches were exported to a Mendeley bibliographic database for deduplication and to Covidence software for screening. One author (IT) screened studies by title and abstract and full text to determine eligibility. Decisions to include were made according to inclusion criteria. **Data extraction and analysis:** A table was created for data extraction (Table 1 in Supplement1) listing authors, year of publishing, country where the study was undertaken, study design, type of cancer, type of disability, type of outcome, population size and overall risk of bias. One author (IT) extracted the data. A summary of study characteristics can be found in

152

153

154

155

156

157

158

159

160

161

162

163

164

165-

166

167-

168

169-

170

171

Table 1. We also created a table with a summary of primary and secondary outcomes of each study (Table 2); where possible, odds or prevalence ratios as a measure of association or *p*-values comparing measures in people with and without disabilities were extracted. Each study was also classified as "better", "worse" or "null", when outcomes respectively showed a better, worse or equal situation in quality of cancer care for PwD in comparison to people without disabilities. A narrative synthesis was conducted according to the Cochrane SWiM guidelines. **Determining risk of bias:** Studies were evaluated for risk of bias based on a set of criteria according to the SIGN 50 (Scottish Intercollegiate Guidelines Network) checklists as explained in Supplement 1. (37) Overall Ratings were summarised as follows (figure 2) with RobVis tool:(38) Low risk of bias: all or almost all of the above criteria were fulfilled, and those that were not fulfilled were thought unlikely to alter the conclusions of the study; Medium risk of bias: some of the above criteria were fulfilled, and those not fulfilled were thought unlikely to alter the conclusions of the study; High risk of bias: few or no criteria were fulfilled, and those that were not fulfilled were thought likely or very likely to alter the conclusions of the study. We did not perform tests to measure publication bias. (39)

Ethical Considerations 172 173 Approval for the review was given by LSHTM MSc Ethics Board (internal ref. 26741). 174 There were no ethical concerns for this literature review. **Financial support and Competing Interests** 175 176 The Authors declare no competing interests; there are no known conflicts of interest 177 associated with this publication and there has been no significant financial support 178 for this work that could have influenced its outcome. 179 180 181 182

Results

The search was conducted on July 13th, 2022 resulting in 4140 titles identified (Figure 1). After removal of 408 duplicates, 3732 titles and abstracts were screened, and 3680 ineligible studies were excluded. Next, 52 full texts were retrieved and 21 were excluded because of ineligible study design, comparator, patient population, outcomes, intervention or setting. Finally, 31 studies were identified as eligible for the systematic review.




Figure 1. PRISMA Flowchart

Study Characteristics Table 1 shows a summary of the characteristics of the 31 studies included in the systematic review. All the studies were conducted in high-income countries, with the greatest proportion coming from the USA (29% of the studies, n=9), followed by South Korea (19%, n=9), Japan (13%, n=4), France (10%, n=3), then by the UK, Netherlands and Sweden with two studies each, and by Belgium, Taiwan and Germany with one study each. Twenty studies (65%) were published after 2018, showing a marked growth in research interest on this topic in the past few years; only 11 eligible studies were published earlier, between 2000 and 2017. A more detailed table of study characteristics is included in Supplement 1.

217 Table 1. Summary of characteristics of included studies.

		N	%
REGION (as per WHO classification)	Western Pacific	14	45%
	European	11	36%
	Americas	9	29%
	African	0	0
	South East Asian	0	0
	Eastern Mediterranean	0	0
STUDY DESIGN	Retrospective cohort	27	87%
	Prospective cohort	3	10%
	Cross-sectional	1	3%
DISABILITY TYPE	Visual	0	0%
	Hearing	0	0%
	Physical	0	0%
	Intellectual-cognitive	9	29%
	Psychosocial	13	42%
	All types	9	29%
SAMPLE SIZE OF PEOPLE WITH DISABILITY	Smallest	46	n/a
	25th percentile	523	n/a
	Median	1016	n/a
	75th percentile	4077	n/a
TYPE OF CANCER	Any	7	23%
	Breast	9	29%
	Stomach and colorectal	4	13%
	Lung	3	10%
	Prostate	2	6%
	Others (Testicular, Multiple Myeloma,		
	Acute Myeloid Leukaemia, Bladder, Oral)	5	16%
	All types	1	3%
RISK OF BIAS	Low	12	39%
	Medium	14	45%
	High	5	16%

Table 2, Outcomes of studies and type of disability

Study Design

Twenty-seven of the 31 studies used a retrospective cohort study design, with data either from a single center (n= 2) or from a national or multi-center health insurance and disability database (n=25), while three studies used a prospective cohort design, one from a single center and two from multi-center hospital networks. One study only used a cross-sectional design with a survey performed among patients of a network of cancer centers.

Types of Disabilities

Over a third of the eligible studies focused on people with psychosocial disability (42%, n=13) defined as a previous diagnosis of psychiatric or mental health issues. (38–53) Nine studies (29%, n=9) focused on intellectual, learning disabilities, cognitive impairment or dementia(54–62)Nine other studies (29%, n=9) considered all disability in general or grouped into subcategories (e.g. physical/communication/mental/internal organ/others). (19,22-23,63–68) Few studies differentiated by severity of impairment. (19,22,64-69)

Types of Cancer

Seven studies (23%) were about any type of malignancy, while almost a third (29%, n=9) were about breast cancer. There were 4 studies (13%) regarding stomach and colorectal malignancies, 3 (10%) on lung cancer, 2 (6%) on prostate cancer, and 1 study each for testicular, multiple myeloma (MM), acute myeloid leukaemia (AML),

bladder and oral cancer. Finally, one study included patients of breast, prostate and colorectal cancers (Table 1).

Types of outcome

The majority of papers (65%, n=20) included a measure of survival or mortality after cancer diagnosis as primary or secondary outcome. Seventeen studies (55%) included an outcome of access to state-of-the-art cancer treatment, measured as type of treatment received (guidelines consistent according to disease stage) or invasiveness of surgery or treatment delay. Four (13%) studies described access to quality of end-of-life care, defined as access to appropriate pain control and end-of-life hospital use for palliative care. One study included access to pain medications as an outcome.

Risk of Bias

Almost half of the 31 studies (45%, n=14) had a medium risk of bias, while 12 studies had a low risk of bias (39%, n=12). Finally, 5 papers were marked as having a high risk of bias. A summary of the assessment of risk of bias, was created with RobVis tool. (38) (Figure 2)

				Risk of bia			
	Mahay	D1	D2	D3	D4	D5	Overall
	Afshar	+	+		+	+	
	Chang	+	•	<u> </u>	•		<u>-</u>
	Cuypers a	+	•	<u>-</u>	<u>-</u>	+	<u>-</u>
	Cuypers b	+	+	-	-	+	-
	Fond	<u>-</u>	+	<u>-</u>	+	+	-
	Fried	+	+	+	+	+	+
	Gross	-	-	-	-	-	X
	Gupta	+	+	-	+	-	-
	lezzoni	+	+	-	+	+	+
	Iglay	+	+	-	+	-	-
	Ishikawa	+	+	+	+	-	+
	Kaneshiro	+	-	-	+	-	X
	Kashyap	+	+	+	+	+	+
	Kim	+	+	+	+	+	+
	Kwon a	+	+	+	+	+	+
Study	Kwon b	+	+	+	+	+	+
	Lawrence	+	+	<u>-</u>	-	+	-
	Libert	<u>-</u>	+	+	+	-	<u>-</u>
	Mahabaleshwarkar	+	+	-	+	-	<u>-</u>
	Martin	+	+	+	-	-	<u>-</u>
	Park	+	+	-	+	+	+
	Robb	+	-	-	+	-	×
	Sathianaten	-	+	-	+	+	-
	Sato	-	-	-	-	-	X
	Segerlantz a	+	+	+	+	+	+
	Segerlantz b	+	+	+	+	+	+
	Shin a	+	+	+	+	+	+
	Shin b	+	+	+	+	+	+
	Shinden	<u>-</u>	<u>-</u>	-	•	-	+ & -
	Tran	+	+	<u>-</u>	+	-	<u>-</u>
	Viprey	<u>-</u>	•	+	-	+	<u>-</u>

Figure 2. Risk of Bias (in alphabetic order)

D1=Selection bias D2=Information bias D3=Misclassification bias; D4=Confounding D5=Missing data;

Green=Low Yellow=Medium Red=High

259

260

261 262

263

Made with Robvis tool. (38)

Outcome Results

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

Outcomes are summarized in Table 2. Nineteen studies that included a measure of survival or mortality all showed, invariably, a direction of effect towards worse outcomes for PwD; this was often worsened by the degree of severity of disability.(19,22,41,54-55,62) Only one study found no difference in overall survival or disease-free survival between patients with and without disabilities. (49) Among psychosocial disabilities, schizophrenia had generally the worst prognosis. (41,47,51,66,70) In studies that examined survival in cancer patients with all types of disability, there seemed to be far worse outcomes for those with severe disabilities and with intellectual impairment. In one study results showed that patients with schizophrenia had a cancer specific mortality rate 50% higher than patients without disabilities. (50) In another study about bladder cancer, the risk of cancer specific death was 35% higher for patients with severe mental illness compared to people without disabilities. (69) In a large study about gastric cancer patients in South Korea, PwD were more likely not to receive proper staging tests to establish an appropriate treatment plan. Observing subgroups by disability type, the fact of not receiving treatment was more common for people with communication impairment (36.9% in severe and 31.4% in mild communication disability); the authors concluded that disability itself should not be а contraindication for receiving cancer treatment. (16) Another study about patients with leukaemia described how the treatment rate was lowest in those with major internal organ and communication disabilities; while for patients with major internal

organ disabilities it is understandable to have a low treatment rate due to vital functions often lacking functional reserve, communication disabilities are not directly related to vital functions and the decision not to treat was hence not based solely on medical factors. (67)

medRxiv preprint doi: https://doi.org/10.1101/2023.04.18.23288733; this version posted July 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Table 2, Outcomes of studies and type of disability

AUTHOR	TYPE OF DISABILITY	PRIMARY OUTCOME	MEASURE IN PWD	MEASURE IN PEOPLE WITHOUT DISABILITIES	EFFECT MEASURE	SECONDARY OUTCOME	MEASURE IN PWD	MEASURE IN PEOPLE WITHOUT DISABILITIES	EFFECT MEASURE	TREND FOR PWD
Afshar(53)	Intellectual (learning disability)	10-yr survival rate	77.6% (95% CI = 72.2– 83.3%)	89.9% (95% CI = 89.4– 90.3%)	10-yr survival relative rate: 12.3% lower for PwD	5-yr survival rate	84% (95% CI = 79.9–88.4%)	92.2% (95% CI = 91.8– 92.5%)	5-yr survival relative rate: 8.2% lower for PwD	WORSE
Chang(51)	Psychosocial (mental illness)	Access to state-of-the-art treatment	68% received surgery	82% received surgery	Adjusted OR of receiving surgery for PwD = 0.47 (95% CI = 0.34–0.65; P=0.001)	5-yr survival rate	50.50%	68.10%	Adjusted relative risk of death 1.58 higher for PwD (95% CI = 1.30–1.93; P,0.001).	WORSE
Cuypers(56)	Intellectual	Cancer- specific mortality	not mentioned	not mentioned	SMR= 1.48; (95% CI = 1.42-1.54) for PwD	n/a	n/a	n/a	n/a	WORSE
Cuypers(70)	Intellectual	Insurance claims for cancer hospital care	IR = 28.9 per 1000 person/year	IR = 45.3 per 1000 person/year	IRR = 0.64 (95% CI = 0.62-0.66) in PwD	n/a	n/a	n/a	n/a	WORSE
Fond (40)	Psychosocial (Severe psychiatric disease)	End-of-life treatment access	Incidence of palliative in month before death = 81.3%	Incidence of palliative in month before death = 75.2%	more trips to palliative care in last month of life (aOR 1.32, 95%CI [1.15–1.51], p<0.001) in last month of life in PwD	Overall survival time (days)	886	918	p value = 0.21	NULL for mortality, WORSE for end-of-life treatment
Fried(41)	Psychosocial (Severe mental illness)	Cancer- specific 5-yr mortality	not mentioned	not mentioned	HR = 1.39 (95% CI: 1.04-1.84) for PwD	Access to state-of-the-art treatment	12.8% received surgery	21.8% received surgery	OR = 0.66 (95% CI: 0.49-0.89) for PwD of receiving surgery	WORSE

Gross(63)	Any	Screening results	not mentioned	not mentioned	PwD less often diagnosed for cancer through a mammograph y screening (OR for patients with physical impairment = 0.70; p < 0.05; OR for Sensory Impairment = 0.58; p < 0.05) than patients without disability.	Invasiveness of treatment	not mentioned	not mentioned	PwD less likely to receive breast conserving treatment (OR 0.58; p < 0.05) and more likely to have a mastectomy without reconstruction (OR = 1.96; p < 0.05) than those without disabilities	WORSE
Gupta(71)	Cognitive (Dementia)	Stage at diagnosis	8.4% diagnosed on autopsy or death certificate	1.9% diagnosed on autopsy or death certificate	aOR = 2.31 (95% CI 1.79–3.00) for PwD to have colon cancer reported only after death (i.e., from autopsy or death certificate)	Access to state-of-the-art treatment	not mentioned	not mentioned	aOR =0.43 (95% CI 0.33-0.70) for PwD to receive surgery; aOR =0.21 (95% CI 0.13-0.36) for PwD to to receive adjuvant chemo	WORSE
lezzoni(62)	Any	Cancer- specific mortality	not mentioned	not mentioned	HR=1.37 (95% CI, 1.24 -1.51) of cancer specific mortality for PwD	Access to state-of-the-art treatment	68.5% received surgery	82.2% received surgery	aRR 0.84 (95% CI 0.79- 0.89) for PwD to receive surgery	WORSE
Iglay(43)	Psychosocial (Mental illness)	Treatment delay	8.60%	8.70%	aRR 1.36 (95% CI 1.06, 1.74) for PwD subgroup with severe mental illness of initial treatment delay at 60 days relative to controls	Diagnosis delay	34.90%	34.80%	aRR 1.11 (95% CI 1.00, 1.23) for PwD subgroup with comorbid anxiety and depression relative to controls	WORSE

Ishikawa(42)	Psychosocial (Schizophreni a)	Overall in- hospital mortality	4.20%	1.80%	OR = 1.35; (95% CI 1.04– 1.75, P= 0.026) for pwd	Stage at diagnosis and access to state-of-the-art treatment	33.9% stage IV; 56.5% surgery	18.1% stage IV; 70.2% surgery	RR 1.86 (95% CI 1.72–2.00; P<0.001) of higher stage at diagnosis and OR = 0.77 (95% CI 0.69–0.85, P=0.001) for access to surgical or endoscopic treatment for PwD	WORSE
Kaneshiro(44)	Psychosocial (Schizophreni a)	Incidence of invasive surgery	84.3% mastectomy	63.2% mastectomy	(P = 0.002)	Access to state-of-the-art treatment	56% received radiotherapy	75% received radiotherapy	(P = 0.078).	WORSE
Kashyap(45)	Psychosocial (Mental illness)	End of life Emergency Department use	15.6% with access to ED in last 30 days of life	13.3% with access to ED in last 30 days of life	p < 0.01	Impact of outpatient mental health treatment in mental illness	not mentioned	not mentioned	aOR 0.82 (95% confidence interval 0.78–0.87) for mental health patients on outpatient mental health treatment to have multiple end-of-life ED visits	WORSE
Kim(22)	Any	Mortality	125.2 per 1000	104.3 per 1000	aHR=1.18 (95% CI: 1.14–1.21) for PWD and aHR = 1.62 (95% CI: 1.56–1.69) for severe disability group	Mortality in patients who received surgery	not mentioned	not mentioned	aHR 1.21 (95% CI: 1.16–1.27), even higher in severe disability group (aHR 1.69, 95% CI: 1.57–1.81),	WORSE
Kwon(19)	Any	Median overall survival	36.8 months	51.2 months	p < 0.001	Access to state-of-the-art treatment	37.5% received transplant	43.7% received transplant	p=0.072	WORSE
Kwon(68)	Any	Median overall survival	10.8 months	17.1 months	p=0.02	Access to state-of-the-art treatment	chemo 71.2% vs 77.1%, P = .0031, and transplant 17.5%	chemo 77.1%; transplant 26.9%	p = 0.0031 and p=0.002	WORSE

Lawrence(67)	Psychosocial (Severe mental illness)	All-cause and cancer-specific mortality	not mentioned	not mentioned	all-cause mortality HR=1.36; (95% CI 1.18, 1.57) and cancer- specific mortality HR=1.21 (95% CI 1.03, 1.44) for women with SMI compared to controls	10-year overall survival	73.10%	78.30%	not mentioned	WORSE
Libert(61)	Cognitive	Overall mortality	12.3% at 2 years	2% at 2 years	HR = 6.13 (95% CI = 2.07–18.09; p = 0.001) for people with cognitive impairment; HR = 3.06; (95% CI = 1.31–7.11, p=0.009) for people with loss of instrumental autonomy	n/a	n/a	n/a	n/a	WORSE
Mahabaleshw arkar(47)	Psychosocial (mental illness)	Access to state-of-the-art treatment	not mentioned	not mentioned	aOR= 0.79 (95% CI= 0.65-0.97) of receiving guideline- consistent breast cancer treatment for PwD	Healthcare utilization	not mentioned	not mentioned	aIRR= 0.92 (95% CI = 0.89-0.94) for breast-cancer related outpatient visits; aIRR = 0.84 (95% CI = 0.71- 0.99) for breast- cancer related ER visits for PwD	WORSE

Martin(54)	Cognitive	Overall mortality	not mentioned	not mentioned	HR 1.39 (95% CI =1.09, 1.78, p>0.01) for PwD	Access to state-of-the-art treatment	22.3% with mild, 35.6% with moderate and 51.8% with severe cognitive impairment received primary endocrine therapy (NOT state of the art)	12.4% women with normal cognition received PET	p <0.001	WORSE
Park(66)	Any	Long-term all- cause mortality of 5- year cancer survivors	not mentioned	not mentioned	Male PwD HR = 1.48 (95% CI 1.33–1.66) and female PwD HR= 1.53 (95% CI, 1.28–1.83) compared with controls	Short-term (<5 years) all- cause mortality	not mentioned	not mentioned	male with impaired communication HR= 1.24 (95% CI, 1.07–1.44), female with internal organ disability HR, 2.20 (95% CI, 1.42–3.42)	WORSE
Robb(57)	Cognitive	Median overall survival	23.0 months (0.2–140.7 months)	72.6 months for controls (0.9–135.5 months)	p < 0.001	n/a	n/a	n/a	n/a	WORSE
Sathianathen(69)	Psychosocial (Mental illness)	Access to state-of-the-art treatment	not mentioned	not mentioned	OR 0.55 (95% CI 0.37– 0.81) for patients with severe mental illness and OR 0.71 (95%CI 0.58– 0.88) for those with depression of receiving curative treatment.	Cancer- specific mortality	not mentioned	not mentioned	severe mental illness patients had HR 1.35 (95% CI1.14–1.61) in both the NMIBC (HR 1.48, 95% CI 115–1.92) and MIBC (HR1.37, 95% CI 1.10–1.72) subgroups, compared with controls	WORSE
Sato(64)	Any	Access to state-of-the-art treatment	not mentioned	not mentioned	difference not significant	n/a	n/a	n/a	n/a	NULL

Segerlantz(59)	Intellectual	Pain control prescription	36%	60%	RR 0.61 (95% CI 0.54-0.69) for PwD to have prescription of COX inhibitors, RR 0.63 (95% CI 0.53-0.73) for weak opioids	Prescription of other drugs	36% on antidepressant s; 47% on anxiolytics	17% on antidepressant s; 16% on anxiolytics	RR 2.09 (95% CI 1.74–2.51) for PwD to be prescribed antidepressant s: RR 2.84 (2.39–3.38) for PwD to be prescribed anxiolytics	WORSE
Segerlantz(58)	Intellectual	Healthcare utilization	1.5 visits per person in final year of life	1.75 visits per person in final year of life	RR 0.90 (95% CI 0.87–0.93) for PwD to be less likely than controls to have >1 visit in specialist inpatient care during last year of life;	Quality of end- of-life care	31% accessed advanced hospital care	55% accessed advanced hospital care	RR 0.57 (95%CI 0.51– 0.64) for PwD to have access to advanced hospital care	WORSE
Shin(68)	Any	Overall mortality	531.2 per 1000	463.1 per 1000	aHR 1.08, (95% CI: 1.06–1.11) for PwD, and subgroup with severe disability HR =1.20 (95% CI: 1.16–1.24)	Access to state-of-the-art treatment	19.8% surgery; 42.3% chemo; 26.4% radiation	21.9% surgery; 46.1 chemo; 27.6% radiation	aOR Surgery= 0.82, (95% CI 0.77-0.86), aOR chemo =0.80, (95% CI: 0.77- 0.84), aOR radiotherapy =0.92 (95% CI: 0.88-0.96) for PwD	WORSE
Shin(65)	Any	Access to state-of-the-art treatment	Surgery 33.1%; ADT 57.9%	Surgery 38.6%; ADT 55%	Surgery aOR=0.79, (95% CI 0.74- 0.84); ADT aOR =1.10 (95% CI1.04- 1.16) for PwD. For severe disability, surgery aOR= 0.60 (95% CI, 0.54-0.67), ADT aOR=1.29 (95% CI, 1.18- 1.42)	Overall mortality and cancer- specific mortality	57.3 per 1000; 26.7 per 1000	43.7 per 1000; 21.7 per 1000	Overall mortality aHR, 1.20 (95% CI, 1.15-1-25) for PwD; with severe disability aHR 1.47 (95% CI 1.37-1.57). Cancerspecific mortality aHR 1.11 for pwd (1.04-1.18), but no difference	WORSE

									when PwD had same access to surgery.		
Shinden(49)	Psychosocial (Mental illness)	Access to state-of-the-art treatment	total mastectomy 78%, postoperative adjuvant chemo 0%, radiation 2%	total mastectomy: 59%; postoperative adjuvant chemo 19%; radiation 18%	p <0.05 for all the mentioned outcomes	Overall survival	not mentioned	not mentioned	no difference	NULL mortality, WORSE treatment	for for
Tran(50)	Psychosocial (Schizophreni a)	Overall mortality and All-cancer- mortality	not mentioned	not mentioned	4-fold higher all-cause mortality for schizophrenia. Cancer SMR = 1.5 (95% CI: 1.2-1.9).	Mortality by cancer type	not mentioned	not mentioned	Male PwD and lung SMR = 2.2 (95% CI, 1.6-3.3); female PwD and breast SMR = 2.8 (95% CI, 1.6-4.9) compared to controls	WORSE	
Viprey(46)	Psychosocial (Schizophreni a)	Access to state-of-the-art treatment	early palliative care: 77%; end-of-life chemo: 10%; end of life surgery: 17%	early palliative care: 72%; end-of-life chemo: 15%; end of life surgery: 20%	aOR for early palliative care= 1.27 (95% Cl=1.03;1.56; p=0.04) , aOR for end-of-life chemo=0.53 (0.41-0.70, p<0.0001), aOR end-of-life surgery =0.73 (0.59;0.90, p<0.01) for PwD.	Quality of end- of-life care	Hospitalization in acute care unit the month before death 33%; median length of last hospital stay 13 days; deaths in the ICU/ED 10%	Hospitalization in acute care unit the month before death 24%; median length of last hospital stay 10 days; deaths in the ICU/ED 11%	aOR for hospitalization in acute care unit the month before death = 1.41 (95% Cl=1.18;1.67; p<0.001); longer length of last hospital stay (Beta=1.22, SD=0.05; p<0.0001); aOR for deaths in the ICU/ED = 0.74	WORSE	

				(95% CI = 0.56;0.97; p = 0.04) for PwD.

LEGEND OF ABBREVIATIONS for Table2:

yr = year; CI = Confidence Interval; OR = Odds Ratio; SMR = Standardized Mortality Ratio; IR = Incidence Rate; IRR = Incidence Rate Ratio; aOR = adjusted Odds Ratio; HR = Hazard Ratio; PWD = PwD; aRR = adjusted Risk Ratio; ED = Emergency Department; aHR = adjusted Hazard Ratio; SMI = Severe Mental Illness; aIRR = adjusted Incidence Rate Ratio; PET = Primary Endocrine Therapy; NMIBC = non-muscle invasive bladder cancer; MIBC = muscle invasive bladder cancer; COX = cyclooxygenase; RR = Relative Risk; ADT = Androgen Deprivation Therapy; ICU = Intensive Care Unit

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

There were 16 studies showing lower chance in receiving state-of-the-art cancer treatment for PwD, and only one study with high risk of bias showed no difference, but data about gender and degree of disability was missing. (64) The studies showed that cancer treatment was suboptimal for PwD in many ways, and in particular that they had a lower likelihood of undergoing guideline-consistent surgery when indicated. (22,23,48,52,61,63,66,70) Several studies showed that when PwD were correctly treated with guideline-consistent surgery, their mortality was similar or only slightly higher than controls. (62,66)PwD were also more likely to face diagnosis and treatment delays - but not when access to screening was optimal, underlining the importance of good screening access. (22,42,43,56,57,71) PwD were also less likely to receive curative-intent transplants for blood cancers, and more likely to receive inappropriate radical mastectomy instead of guidelineconsistent minimally invasive procedures for breast cancer (19,44,63,67) As for end-of-life and palliative care, 4 studies showed a direction of effect towards worse outcomes for PwD (40,45,46,58). One of this studies, with low risk of bias, showed an association between receiving outpatient treatment from a mental health professional and having less end-of-life ED visits, suggesting the importance of access to mental health services to improve end-of-life care. (45) One study showed an association between disability and worse access to prescriptions for pain treatment during cancer care, a situation likely to severely compromise quality of life. (59) Finally, a study reported that patients over age 55 with intellectual disability were more likely than controls to have worse access to specialist care in the last year of life. (58)

Regarding other factors contributing to worse outcomes, one study showed an association between worse access to screening programs (for breast, colon and cervix cancers) and higher cancer specific mortality, underlining the inequality in screening practices. (56) Two other studies highlighted an association between barriers to screening and worse outcomes for gastric and breast cancer in PwD. (22,44) Two studies detected even worse disparities in access to state-of-the-art treatment or end-of-life care related to ethnicity and age, with young disabled nonwhite men having the worst outcomes. (45, 62) One study of people with intellectual disabilities with any type of cancer suggested worse underdiagnosis for older females, while another focusing on breast cancer detected an association between physical disability and inappropriate invasiveness of treatment. (55, 63) In a study of non-small cell lung cancer patients, those with respiratory or nervous system disabilities had the lowest chance of receiving guideline-appropriate surgery, while another paper on lung cancer recorded the worst access to treatment among people with communication or neurologic disabilities. (23, 62) A study about stomach cancer and patients with all kinds of disabilities also found an association between worse outcomes and severe intellectual impairment. (22)

Finally, three studies showed an association between worse outcomes of treatment access and poverty among people with cancer. (19, 46, 68)

Discussion

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

In our review, compared to people without disabilities, PwD were found to have worse survival, higher overall and cancer-specific mortality, loss of chance for

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

access to state-of-the-art care or curative-intent therapies, treatment delays, undertreatment or excessively invasive treatment, worse access to in-hospital services, less specialist healthcare utilization, more difficult access to pain medications and inadequate end-of-life quality of care. Only one eligible study found no difference in overall survival or disease-free survival between patients with and without disabilities; it was a small paper with a high risk of bias, with a cohort including only operable breast cancer in a small number of patients, and it still showed an association between disability and excessively invasive breast surgery without any clear cancer-related clinical reason. Furthermore, the incidence of disability in its retrospective cohort was inexplicably only half of the known national incidence, suggesting severe misclassification bias. (49)These finding suggest that differences in frequency of appropriate treatment appear to explain the higher cancer-specific mortality for this vulnerable population, with higher mortality likely due to loss of chance and unequal clinical care. Even if sometimes treatment decisions for PwD can be clinically complex, such as the above-mentioned case of cognitive impairment with legal consent or non-compliance issues, or when confronted with a disability-related shortened life expectancy or frailty for some syndromes, there is no plausible medical justification for such a wide disparity compared to patients without disabilities, and these results raise severe concerns about equality in cancer care.(25-26,70-74) The results of this study are consistent with those of other recent literature reviews, showing that PwD experience inequities at several points throughout the cancer care pathway. (12,24,26,73-74) Screening disparities have been known and documented for years: they can vary by disability type, severity, healthcare offer and social or demographic situations, with some differences across countries, but globally there is

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

a largely similar trend of major barriers to screening for people with disability, showing a clear need to improve the inclusiveness of these early-diagnosis services.(12, 71-75) Providing equitable cancer care has to start early in the cancer clinical pathway, because delays in receiving a diagnosis tend to lead to late access to treatment and worse outcomes.(70-74) A frequently observed issue is that new signs and symptoms tend to be attributed to often to the underlying disability, a clinical mistake called "diagnostic overshadowing". (72-76) A recent scoping review about cancer outcomes in adults with intellectual and developmental disabilities has described disparities at every step of the way, from screening, to staging, to treatment and survival outcomes, recognizing how these experiences do not originate simply from a gap in early diagnosis, but from larger structural issues that ultimately hinders quality of the entire cancer care pathway. (74,77) Another review of cancer treatments for people with intellectual disabilities highlighted possible themes that might interfere with treatment, such as genetic syndrome frailty that might render certain drug treatments too dangerous, the issue of behavioral non-compliance in a subgroup of patients, and problems related to legal capacity and obtainment of informed consent. Still, these three factors should not represent an insurmountable barrier because with appropriate arrangements (e.g. pharmacology consults, procedural sedation, legal assistance) it should still be possible to offer guideline-consistent treatment to With physical disabilities clinical decisions can sometimes be patients.(25-26) objectively more difficult than in people without disabilities, because of concerns about baseline performance status or competing health risks due to invasive or toxic treatments that might result in further dramatic loss of function (e.g. possible loss of postoperative upper limb function after breast surgery in patients with previous spinal

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430


431

432

cord injury and lower limb paralysis); this has been described as a compelling reason to move towards better cooperation between cancer care clinicians and disability specialists who have been in charge of the patient well before their oncology episode, and also as one of the fundamental facts that make shared decision making with patients (or sometimes their families or caregivers) of the utmost importance.(12) This clear evidence of inequities emphasizes the very urgent need for better cancer care for PwD. Furthermore, disparity in healthcare for PwD is not unique to oncology, as research about the recent Covid-19 pandemic has clearly proven. (77-82) During the pandemic, PwD have died in disproportionate numbers – almost three times as much globally than people without disabilities - and have been excluded from the decision-making process, because their needs have been ignored; they have ended up facing an increasing amount of psychological distress, lack of social support, extreme isolation, food insecurity, disparities in health care access and even discrimination at work. In many cases, government response has compromised the human rights of disabled people, having exposed and magnified existing structural failings and inequalities.(80-85) Recently, the second report of the Missing Billion Initiative has called for reimagining health systems with a vision of inclusive health informed by diverse perspectives of PwD, who are still facing worse health outcomes across SDG3 indicators (Sustainable Development Goal 3 by the WHO, i.e. ensure healthy lives and promote well-being for all at all ages), globally and with all sort of impairment types. (84) The first Missing Billion report had highlighted a substantial life expectancy gap of 10-20 years for PwD, with all-cause mortality rates

approximately twice as high as those of people without disabilities. (83) Closing this gap is now a priority, but it requires long-term investments to design from the start health systems that expect, accept and connect PwD, with sufficient earmarked funds, dedicated leadership and clear governance based on data and evidence disaggregated by disability. Ideally service delivery should aim at affordability, autonomy of patients, accessibility, specific workforce skillsets and availability of rehabilitation services. (82-86) The multiple barriers experienced by PwD during their cancer care (Figure 3) are hence a reflection of a broader process of discrimination and disadvantage, mirrored in structural failings of current healthcare systems, within networks of intersecting factors that ultimately influence cancer outcomes. (24, 82-87)

Figure 3: Barriers experienced by PwD during cancer care



Healthcare workers need to receive evidence-based and appropriate training about disabilities, directly involving PwD and using a monitoring system to measure cultural progress and outcome improvement. This could help foster a change to move away from the ableist attitudes that are too often still observed, contributing to wrong assumptions and subsequent mistakes of diagnostic overshadowing or failure to anticipate specific complications (12,75,86-88). In a very recent qualitative study from the USA, interviewed physicians, mostly middle-aged white males, felt inadequately reimbursed for accommodations required by the 1990 Americans with Disabilities Act; according to some of these doctors, these concerns simply led them to discharge patients with disabilities. (86) Many physicians openly spoke about the lack of accessibility in their clinics without any plans to improve it, and several

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

demonstrated a complete lack of disability knowledge about how to manage very basic issues – even stating that they were regularly sending patients to a zoo, cattle processing plant or supermarket to obtain a weight if a patient was in a wheelchair and unable to stand; several doctors admitted that they rarely spoke to these patients, regardless of the patients' ability to communicate, and that information was almost exclusively obtained from the caregiver. This confirms findings from previous qualitative research, that had described a lack of skills by healthcare workers to feel empathy for the embodied experience of living with a disability, with an obstinate resistance to adapting their habitual practice to these patients. (10) The importance of inclusive clinical trials to close the evidence gap about what works to improve cancer care for PwD cannot be overemphasized (86-90). There is still too little evidence about how to treat cancer in the population with disabilities, which is very diverse and can have widely different therapeutic needs (hence existing services must be offered in a flexible, respectful, inclusive and accessible way to be relevant for this patient population). Thus it is of the utmost importance to include PwD in clinical trials in oncology - both for curative-intent interventions and for palliative treatments; yet, historically they have been left out of studies, due to many

palliative treatments; yet, historically they have been left out of studies, due to many factors such as ableist prejudice, or multiple barriers such as accessibility of research facilities and access to transportation, or lack of caregivers' engagement. (87-92) Unfortunately, in clinical trials pre-existing conditions are often excluded, even if the conditions have little bearing on the treatment being tested or the outcome of the trial. Excluding disabled individuals from a study can result in a study population that does not even represent the general population, since disability often correlates with other inequalities (such as poverty and unemployment). The importance of targeting the recruitment of disabled individuals into clinical trials, as

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

well as considering the unique barriers and motivations of this population, needs to be highlighted. A person with a disability may have difficulty traveling to a trial site; moreover, healthcare organizations should consider their audiences' digital literacy and the accessibility of their communications. Funds should be allocated to improve healthcare communication, adapting multiple formats, using captions and alt-text or pictorial representations of concepts as appropriate for the specific context. In addition, disabled individuals appear to be underrepresented as investigators in scientific research. (89-93) Despite 19% of the UK's general population identifying as disabled, only 4% of academic, research, and teaching staff do. Even if 25% of American adults live with a disability, in 2020 only 4% of US STEM PhDs were awarded to people with impaired hearing or vision, and just 1% to people with a mobility limitation. More disability-confident schemes and unconscious bias training could at least partially mitigate hiring discrimination, creating an academic workforce that better reflects the community in which it is based.(90-94) Recent evidencebased recommendations to promote inclusion in clinical trials include improving culture and sensitivity of staff through continuous education, receiving ongoing feedback from a community advisory panel during studies and increasing staff diversity to make sure underprivileged groups are represented. (91-94) Physicians and PwD should be able to collaborate along care pathways with shareddecision making, an approach based not only on clinical technical advice but on the life experience of patients, their caregivers and families, according to the principle of "Nothing About Us Without Us".(12) In the clinical setting, barriers in physical access should be removed to avoid unacceptable delays in diagnosis and treatment. (10, 91-94) Barriers in communication should be eliminated at several levels, from overcoming communication obstacles (not only for the hearing or visually impaired

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

patients, but also with special-needs assistance for intellectual disability), to improving education of patients, clinicians and caregivers about cancer and the importance of screening, to training healthcare workers about the emotional and physical needs of PwD, enhancing cooperation with other specialists caring for them, in cross-functional teams, to anticipate and possibly reduce the impact of complications, with the goal of a patient-centred pathway. (93-94) Good communication is the foundation of achieving quality patient-centered care: assumptions about preferences can pose a risk like inaccurate information leading to medical errors and misdiagnoses. A recent qualitative study in the USA has shown that, in spite of healthcare workers trying their best, there are still many unsolved issues at this level and even many situations where physicians' preferences go against patients'wishes.(91-94) The strengths of this study include having followed PRISMA and ICM50 guidelines for systematic reviews; furthermore, the search strategy was based on a list of proven disability-specific terms and applied to the five largest medical databases analysing a twenty-year span of publications. This work has several limitations: firstly, the search strategy, limited to five databases and to English language only, might not be fully comprehensive; we did not include studies published in non-English languages because of resource challenges with respect to costs, time, and expertise in non-English languages, but their inclusion would have likely increased generalizability and reduced the overall risk of bias. Furthermore all the eligible papers were from high-income countries, limiting the generalizability of the results, even if there is no reason why the situation should be very different in low and middle-income countries., Qualitative papers and grey literature were not included in the search strategy, hence the views and opinions of PwD about their cancer care

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

were not investigated. Study selection was performed by only one reviewer, which implies a lack of independent screening. We also did not perform tests to measure publication bias due to the high heterogeneity of the eligible studies; although methods exist for simultaneous assessment of heterogeneity and publication bias, and potential differential publication bias, they require very large meta-analysis to reliably disentangle their effects.(39) Moreover, only one reviewer evaluated papers for risk of bias. Finally, the findings were very diverse hence it was not possible to conduct a meta-analysis, and approximately 15% of the studies had a high risk of bias. Almost half (45%) of the eligible studies had a medium risk of bias, mostly due to possible misclassification bias for inclusion of PwD based on disability records (that have a tendency to miss mild cases) CIT or missing data like details about cancer treatment goals, behavioral factors or date of diagnosis. Approximately 15% of the studies had a high risk of bias due to factors such as having a very small sample size, a short follow-up, low data quality, a biased cohort or using a selfreporting survey. (44,49,57,63,64)There are still gaps in knowledge about quality of cancer care for people with disability that remain unanswered based on our findings, such as whether certain subgroups of disabilities or cancer types experience more significant disparities, or how other social determinants of health might come into play (as many PwD are caught in a cycle of poverty and deprivation); more data is needed on these topics to allow disaggregated analyses. Further research is also needed to evaluate the effectiveness of specific training of healthcare workers on quality of care for these patients. In conclusion, PwD often experience severe disparities in cancer care compared to people without disabilities; physical and cultural barriers at different levels must be eliminated to ensure they receive equitable care. There is an urgent need for a

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

robust health policy effort by governments, reimagining health systems with a vision of inclusive health and a sustained commitment, building on decades of progress on disability rights and engaging the participation of PwD at all levels. **Acknowledgments** I.T. would like to thank Danae Rodriguez Gatta, for assistance with disability search terms, and Dr. Meena Cherian, for many fruitful discussions about health systems and development goals. References 1. World Health Organisation. Cancer Fact Sheet [Internet]. 2022 [cited 2022 Apr 13]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer 2. WHO, International Agency for Research on Cancer. Globocan 2020 - Incidence and mortality statistics (all cancers excl. non-melanoma skin cancer). 2020. 3. WHO. Cancer - Screening and early detection [Internet]. [cited 2022 Oct 30]. Available from: https://www.who.int/europe/news-room/fact-sheets/item/cancerscreening-and-early-detection-of-cancer 4. Olusola P, Banerjee HN, Philley J V., Dasgupta S. Human Papilloma Virus-

Associated Cervical Cancer and Health Disparities. Cells. 2019 Jun 21;8(6):622.

579580581	5.	Manz CR, Odayar VS, Schrag D. Disparities in cancer prevalence, incidence, and mortality for incarcerated and formerly incarcerated patients: A scoping review. Cancer Med. 2021 Oct 1;10(20):7277–88.
582 583 584	6.	Williams AD, Buckley M, Ciocca RM, Sabol JL, Larson SL, Carp NZ. Racial and socioeconomic disparities in breast cancer diagnosis and mortality in Pennsylvania. Breast Cancer Res Treat. 2022 Feb 1;192(1):191–200.
585 586	7.	Lee RJ, Madan RA, Kim J, Posadas EM, Yu EY. Disparities in Cancer Care and the Asian American Population. Oncologist. 2021 Jun 1;26(6):453–60.
587 588 589	8.	Davies A, Gurney J, Garvey G, Diaz A, Segelov E. Cancer care disparities among Australian and Aotearoa New Zealand Indigenous peoples. Curr Opin Support Palliat Care. 2021 Sep 1;15(3):162–8.
590 591 592 593	9.	Ellis L, Canchola AJ, Spiegel D, Ladabaum U, Haile R, Gomez SL. Racial and Ethnic Disparities in Cancer Survival: The Contribution of Tumor, Sociodemographic, Institutional, and Neighborhood Characteristics. J Clin Oncol. 2018 Jan 1;36(1):25–33.
594 595 596	10.	Sakellariou D, Anstey S, Gaze S, Girt E, Kelly D, Moore B, et al. Barriers to accessing cancer services for adults with physical disabilities in England and Wales: an interview-based study. BMJ Open. 2019;9(6):e027555.
597 598 599	11.	WHO. Global report on health equity for persons with disabilities [Internet]. World Health Organization., editor. WHO; 2021 [cited 2023 Feb 19]. Available from: https://www.who.int/publications/i/item/9789240063600
600 601	12.	lezzoni LI. Cancer detection, diagnosis, and treatment for adults with disabilities. Lancet Oncol. 2022 Apr 1;23(4):e164–73.
602 603 604	13.	Steele CB, Townsend JS, Courtney-Long EA, Young M. Prevalence of Cancer Screening Among Adults With Disabilities, United States, 2013. Prev Chronic Dis. 2017 Jan;14:E09.
605 606 607	14.	Horner-Johnson W, Dobbertin K, Iezzoni LI. Disparities in receipt of breast and cervical cancer screening for rural women age 18 to 64 with disabilities. Womens Health Issues. 2015;25(3):246–53.

- 608 15. Abrams MT, Myers CS, Feldman SM, Boddie-Willis C, Park J, McMahon RP, et al.
- 609 Cervical cancer screening and acute care visits among Medicaid enrollees with
- 610 mental and substance use disorders. Psychiatr Serv. 2012 Aug 1;63(8):815–22.
- 611 16. Kim YJ, Shin DW, Kim HW, Jung JH, Han K, Cho IY, et al. Disparities in gastric
- 612 cancer screening among people with disabilities: a national registry-linkage study in
- 613 South Korea. Gastric Cancer. 2020 May 1;23(3):497–509.
- 614 17. Horner-Johnson W, Dobbertin K, Andresen EM, lezzoni LI. Breast and cervical cancer
- screening disparities associated with disability severity. Women's Health Issues. 2014
- 616 Jan;24(1).
- 617 18. Courtney-Long E, Armour B, Frammartino B, Miller J. Factors associated with self-
- 618 reported mammography use for women with and women without a disability. J
- 619 Womens Health (Larchmt). 2011 Sep 1;20(9):1279–86.
- 620 19. Kwon J, Kim SY, Yeob KE, Han HS, Lee KH, Shin DW, et al. The Effect of Disability
- on the Diagnosis and Treatment of Multiple Myeloma in Korea: A National Cohort
- 622 Study. Cancer Res Treat. 2020 Jan;52(1):1–9.
- 623 20. Bergamo C, Sigel K, Mhango G, Kale M, Wisnivesky JP. Inequalities in lung cancer
- care of elderly patients with schizophrenia: an observational cohort study. Psychosom
- 625 Med. 2014;76(3):215–20.
- 626 21. Huang HK, Wang YW, Hsieh JG, Hsieh CJ. Disparity of end-of-life care in cancer
- 627 patients with and without schizophrenia: A nationwide population-based cohort study.
- 628 Schizophr Res. 2018;195:434–40.
- 629 22. Kim HW, Shin DW, Yeob KE, Cho IY, Kim SY, Park SM, et al. Disparities in the
- 630 diagnosis and treatment of gastric cancer in relation to disabilities. Clin Transl
- 631 Gastroenterol. 2020 Oct 1;11(10):1–12.
- 632 23. Shin DW, Cho JH, Noh JM, Han H, Han K, Park SH, et al. Disparities in the Diagnosis
- and Treatment of Lung Cancer among People with Disabilities. J Thorac Oncol. 2019
- 634 Feb;14(2):163-75.
- 635 24. M S, A A, H OK, J H, S S, C K, et al. A scoping review documenting cancer outcomes
- and inequities for adults living with intellectual and/or developmental disabilities. Eur J
- 637 Oncol Nurs. 2021 Oct;54:102011.

638 639 640 641	25.	Andiwijaya FR, Davey C, Bessame K, Ndong A, Kuper H. Disability and Participation in Breast and Cervical Cancer Screening: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health [Internet]. 2022 Aug 1 [cited 2023 Jul 24];19(15). Available from: /pmc/articles/PMC9368105/
642 643 644	26.	Liao CM, Huang WH, Kung PT, Chiu LT, Tsai WC. Comparison of colorectal cancer screening between people with and without disability: a nationwide matched cohort study. [cited 2023 Jul 24]; Available from: https://doi.org/10.1186/s12889-021-11105-z
645 646 647 648	27.	Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. 2021 Mar 29 [cited 2023 Feb 19];372. Available from: https://www.bmj.com/content/372/bmj.n71
649 650	28.	Tosetti I, Kuper H. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=281506. 2022.
651 652 653 654	29.	International Classification of Functioning, Disability and Health (ICF) [Internet]. [cited 2022 Oct 20]. Available from: https://www.who.int/standards/classifications/international-classification-of-functioning-disability-and-health
655 656 657	30.	lezzoni LI, Rao SR, Agaronnik ND, El-Jawahri A. Associations between Disability and Breast or Cervical Cancers, Accounting for Screening Disparities. Med Care. 2021 Feb 1;59(2):139–47.
658 659 660	31.	Andresen EM, Peterson-Besse JJ, Krahn GL, Walsh ES, Horner-Johnson W, lezzoni LI. Pap, mammography, and clinical breast examination screening among women with disabilities: A systematic review. Women's Health Issues. 2013 Jul;23(4).
661 662 663 664	32.	A systematic review of the barriers and facilitators influencing the cancer screening behaviour among people with intellectual disabilities - ScienceDirect [Internet]. [cited 2023 Feb 19]. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1877782121002010
665 666	33.	Connolly J. Barriers to access to cancer screening for people with learning disabilities: a review. The Lancet. 2013 Nov;382:S29.

- 667 34. Andiwijaya FR, Davey C, Bessame K, Ndong A, Kuper H. Disability and Participation 668 in Breast and Cervical Cancer Screening: A Systematic Review and Meta-Analysis. 669 Int J Environ Res Public Health. 2022 Aug 1;19(15). 670 35. Chan DNS, Law BMH, Au DWH, So WKW, Fan N. A systematic review of the barriers 671 and facilitators influencing the cancer screening behaviour among people with 672 intellectual disabilities. Cancer Epidemiol. 2022 Feb 1;76:102084. 673 Steele CB, Townsend JS, Courtney-Long EA, Young M. Prevalence of Cancer 36. 674 Screening Among Adults With Disabilities, United States, 2013. Prev Chronic Dis. 675 2019;14. 676 37. Healthcare Improvement Scotland. SIGN 50. 2011; 677 38. McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and 678 Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021 679 Jan 1;12(1):55–61. 680 39. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L, Moreno SG. Assessing 681 publication bias in meta-analyses in the presence of between-study. Vol. 173, Source: 682 Journal of the Royal Statistical Society. Series A (Statistics in Society). 2010. 683 40. Baumstarck K, Viprey M, Auquier P, Fond G, Pauly V, Duba A, et al. End of life breast 684 cancer care in women with severe mental illnesses. Sci Rep [Internet]. 685 2021;11(1):10167. Available from: 686 http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexa&NEWS=N&A 687 N=635041696 688 D.A. F, H. SN, D. G, S. Z, W. H, S.H. G, et al. Impact of serious mental illness on the 41. 689 treatment and mortality of older patients with locoregional high-grade (nonmetastatic) 690 prostate cancer: retrospective cohort analysis of 49 985 SEER-Medicare patients 691 diagnosed between 2006 and 2013. Cancer Med [Internet]. 2019;8(5):2612–22. 692 Available from: http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2045-7634 693 42. H. I, H. Y, H. M, K. F. Differences in cancer stage, treatment and in-hospital mortality
 - http://bjp.rcpsych.org/content/208/3/239.full-text.pdf+html

between patients with and without schizophrenia: Retrospective matched-pair cohort

study. British Journal of Psychiatry [Internet]. 2016;208(3):239-44. Available from:

694

695

696

- 697 43. Iglay K, Santorelli ML, Rhoads GG, Demissie K, Hirshfield KM, Williams JM, et al.
- 698 Diagnosis and treatment delays among elderly breast cancer patients with pre-
- existing mental illness. Breast Cancer Res Treat [Internet]. 2017;166(1):267–75.
- 700 Available from: http://www.wkap.nl/journalhome.htm/0167-6806
- 701 44. K. K, M. K, M. T, M. Y, Y. S, M. K, et al. Current Status and Problems of Breast
- 702 Cancer Treatment with Schizophrenia. Clin Breast Cancer [Internet].
- 703 2022;22(4):e399–406. Available from: http://www.journals.elsevier.com/clinical-breast-
- 704 cancer
- 705 45. M. K, J.P. H, D.T. C, Pollom E.L. AO Kashyap Daniel T.; ORCID:
- 706 http://orcid.org/0000-0003-2760-1554 AO Pollom, Ergi L.; ORCID:
- 707 http://orcid.org/0000-0003-2908-6293 AO Harris, Jeremy P.; ORCID:
- 708 http://orcid.org/0000-0001-7603-0263 MO http://orcid.org/0000 0002 7336 1056
- AOC. Impact of mental illness on end-of-life emergency department use in elderly
- 710 patients with gastrointestinal malignancies. Cancer Med [Internet]. 2021;10(6):2035–
- 711 44. Available from: http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2045-7634
- 712 46. M. V, V. P, S. S, K. B, V. O, P.-M. L, et al. Palliative and high-intensity end-of-life care
- in schizophrenia patients with lung cancer: results from a French national population-
- 714 based study. Eur Arch Psychiatry Clin Neurosci [Internet]. 2021;271(8):1571–8.
- 715 Available from: https://www.springer.com/journal/406
- 716 47. R. M, R. K, B. B, D. WS, Y. Y. Impact of preexisting mental illnesses on receipt of
- 717 guideline-consistent breast cancer treatment and health care utilization. Popul Health
- 718 Manag [Internet]. 2015;18(6):449–58. Available from:
- 719 http://www.liebertonline.com/loi/pop
- 720 48. N.J. S, Y. F, S.L. J, I. K, C.J. W, S. V, et al. Disparities in Bladder Cancer Treatment
- and Survival Amongst Elderly Patients with a Pre-existing Mental Illness. Eur Urol
- 722 Focus [Internet]. 2020;6(6):1180–7. Available from:
- 723 http://www.journals.elsevier.com/european-urology-focus
- 724 49. Shinden Y, Kijima Y, Hirata M, Nakajo A, Tanoue K, Arigami T, et al. Clinical
- 725 characteristics of breast cancer patients with mental disorders. Breast. 2017
- 726 Dec;36:39-43.
- 727 50. Tran E, Rouillon F, Loze JY, Casadebaig F, Philippe A, Vitry F, et al. Cancer mortality
- 728 in patients with schizophrenia: an 11-year prospective cohort study. Cancer [Internet].

- 729 2009;115(15):3555–62. Available from:
- 730 http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med7&NEWS=N&AN
- 731 =19548261
- 732 51. T.-S. C, S.-J. H, Y.-C. S, L.-F. C, H.-C. H, M.-S. L, et al. Disparities in Oral Cancer
- 733 Survival among Mentally III Patients. PLoS One [Internet]. 2013;8(8):e70883.
- 734 Available from: http://www.plosone.org/article/fetchObjectAttachment.action
- 735 52. W.R. L, M.G. K, A.S. H, M.C. L, X. Z, W. Z, et al. Association between preexisting
- 736 mental illnesses and mortality among medicaid-insured women diagnosed with breast
- 737 cancer. Soc Sci Med [Internet]. 2021;270:113643. Available from:
- 738 http://www.elsevier.com/locate/socscimed
- 739 53. Afshar M, O'Neill T, Patel HRH, De-Santis M, Tanner JR, Evison F, et al. Do Learning
- 740 Disabilities Affect Testicular Cancer Survival: A National Cohort Study Between 2001
- and 2015. Eur Urol Oncol [Internet]. 2020;3(6):773–9. Available from:
- 742 https://www.journals.elsevier.com/european-urology-oncology
- 743 54. C. M, A. S, J. M, M. B, E. H, M. B, et al. Treatment choices for older women with
- primary operable breast cancer and cognitive impairment: Results from a prospective,
- 745 multicentre cohort study. J Geriatr Oncol [Internet]. 2021;12(5):705–13. Available
- 746 from:
- 747 http://www.elsevier.com/wps/find/journaldescription.cws home/723463/description#de
- 748 scription
- 749 55. Cuypers M, Schalk BWM, Boonman AJN, Naaldenberg J, Leusink GL. Cancer-related
- 750 mortality among people with intellectual disabilities: A nationwide population-based
- 751 cohort study. Cancer. 2022;128(6):1267–74.
- 752 56. Cuypers M, Tobi H, Huijsmans CAA, van Gerwen L, Ten Hove M, van Weel C, et al.
- 753 Disparities in cancer-related healthcare among people with intellectual disabilities: A
- 754 population-based cohort study with health insurance claims data. Cancer Med. 2020
- 755 Sep;9(18):6888-95.
- 756 57. Robb C, Boulware D, Extermann M, Overcash J. Patterns of care and survival in
- 757 cancer patients with cognitive impairment. Crit Rev Oncol Hematol [Internet].
- 758 2010;74(3):218–24. Available from:
- 759 http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed11&NEWS=N&
- 760 AN=50622380

- 761 58. Segerlantz M, Axmon A, Ahlström G. End-of-life care among older cancer patients
- 762 with intellectual disability in comparison with the general population: a national
- register study. J Intellect Disabil Res. 2020 May;64(5):317–30.
- 764 59. Segerlantz M, Axmon A, Gagnemo Persson R, Brun E, Ahlström G. Prescription of
- pain medication among older cancer patients with and without an intellectual
- 766 disability: a national register study. BMC Cancer. 2019 Nov;19(1):1040.
- 767 60. S.K. G. Patterns of presentation, diagnosis, and treatment in older patients with colon
- cancer and comorbid dementia. J Am Geriatr Soc. 2004;52(10):1681–7.
- 769 61. Slachmuylder JL, Libert Y, Dubruille S, Borghgraef C, Merckaert I, Paesmans M, et al.
- 770 Vulnerabilities in older patients when cancer treatment is initiated: Does a cognitive
- 771 impairment impact the two-year survival? PLoS One [Internet]. 2016;11(8):e0159734.
- 772 Available from:
- http://journals.plos.org/plosone/article/asset?id=10.1371%2Fjournal.pone.0159734.P
- 774 DF
- 775 62. lezzoni LI, Ngo LH, Li D, Roetzheim RG, Drews RE, McCarthy EP. Treatment
- 776 disparities for disabled medicare beneficiaries with stage I non-small cell lung cancer.
- 777 Arch Phys Med Rehabil. 2008 Apr;89(4):595–601.
- 778 63. Gross SE, Pfaff H, Swora M, Ansmann L, Albert US, Gross-Kunkel A. Health
- 779 disparities among breast cancer patients with/without disabilities in Germany. Disabil
- 780 Health J. 2020;13(2).
- 781 64. Sato S, Tanimoto A, Yanagimura N, Suzuki C, Takumi Y, Nishiyama A, et al. Multi-
- 782 institutional survey of cancer disparities in disabled patients in the region of
- 783 northwestern Japan. Int J Clin Oncol [Internet]. 2021;26(6):1009–14. Available from:
- 784 http://link.springer.de/link/service/journals/10147/index.htm
- 785 65. Shin DW, Park J, Yeob KE, Yoon SJ, Jang S nang, Kim SY, et al. Disparities in
- prostate cancer diagnosis, treatment, and survival among men with disabilities:
- 787 Retrospective cohort study in South Korea. Disabil Health J. 2021 Oct 1;14(4).
- 788 66. Park SM, Son KY, Park JH, Cho B. Disparities in short-term and long-term all-cause
- 789 mortality among Korean cancer patients with and without preexisting disabilities: a
- 790 nationwide retrospective cohort study. Support Care Cancer. 2012 May;20(5):963–70.

- 791 67. Kwon J, Kim SY, Yeob KE, Han HS, Lee KH, Shin DW, et al. Differences in diagnosis,
- 792 treatment, and survival rate of acute myeloid leukemia with or without disabilities: A
- 793 national cohort study in the Republic of Korea. Cancer Med. 2020 Aug 1;9(15):5335-
- 794 44.
- 795 68. Shin DW, Cho JH, Noh JM, Han H, Han K, Park SH, et al. Disparities in the Diagnosis
- 796 and Treatment of Lung Cancer among People with Disabilities. Journal of Thoracic
- 797 Oncology. 2019 Feb 1;14(2):163-75.
- 798 69. Sathianathen NJ, Fan Y, Jarosek SL, Konety I, Weight CJ, Vinogradov S, et al.
- 799 Disparities in Bladder Cancer Treatment and Survival Amongst Elderly Patients with a
- Pre-existing Mental Illness. Eur Urol Focus [Internet]. 2020 Nov;6(6):1180–7.
- Available from: http://www.journals.elsevier.com/european-urology-focus
- 802 70. Cuypers M, Tobi H, Huijsmans CAA, van Gerwen L, ten Hove M, van Weel C, et al.
- Disparities in cancer-related healthcare among people with intellectual disabilities: A
- population-based cohort study with health insurance claims data. Cancer Med. 2020
- 805 Sep 1;9(18):6888–95.
- 806 71. Gupta SK, Lamont EB. Patterns of presentation, diagnosis, and treatment in older
- 807 patients with colon cancer and comorbid dementia. J Am Geriatr Soc [Internet].
- 808 2004;52(10):1681–7. Available from:
- http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN
- 810 =15450045
- 811 72. Reeves C, Collingridge D. Improving cancer care for people with disabilities. Lancet
- 812 Oncol. 2022 Apr 1;23(4):446–7.
- 813 73. Boonman AJ, Cuypers M, Leusink GL, Naaldenberg J, Bloemendal HJ. Cancer
- 814 treatment and decision making in individuals with intellectual disabilities: a scoping
- 815 literature review. Lancet Oncol. 2022 Apr;23(4):e174–83.
- 816 74. Andiwijaya FR, Davey C, Bessame K, Ndong A, Kuper H. Disability and Participation
- 817 in Breast and Cervical Cancer Screening: A Systematic Review and Meta-Analysis.
- 818 Int J Environ Res Public Health. 2022 Aug 1;19(15).
- 819 75. Shefer G, Henderson C, Howard LM, Murray J, Thornicroft G. Diagnostic
- 820 overshadowing and other challenges involved in the diagnostic process of patients
- 821 with mental illness who present in emergency departments with physical symptoms--a
- 822 qualitative study. PLoS One. 2014 Nov 1;9(11).

823 824 825 826	76.	Stirling M, Anderson A, Ouellette-Kuntz H, Hallet J, Shooshtari S, Kelly C, et al. A scoping review documenting cancer outcomes and inequities for adults living with intellectual and/or developmental disabilities. EUROPEAN JOURNAL OF ONCOLOGY NURSING. 2021;54.
827 828 829 830	77.	Hillgrove T, Blyth J, Kiefel-Johnson F, Pryor W. A synthesis of findings from 'rapid assessments' of disability and the COVID-19 pandemic: Implications for response and disability-inclusive data collection. Int J Environ Res Public Health. 2021 Sep 1;18(18).
831 832	78.	Shakespeare T, Ndagire F, Seketi QE. Triple jeopardy: disabled people and the COVID-19 pandemic. Lancet. 2021 Apr 10;397(10282):1331–3.
833 834 835	79.	Banks LM, Davey C, Shakespeare T, Kuper H. Disability-inclusive responses to COVID-19: Lessons learnt from research on social protection in low- and middle-income countries. World Dev. 2021 Jan 1;137.
836 837 838	80.	Williamson EJ, McDonald HI, Bhaskaran K, Walker AJ, Bacon S, Davy S, et al. Risks of covid-19 hospital admission and death for people with learning disability: population based cohort study using the OpenSAFELY platform. BMJ. 2021 Jul 14;374.
839 840 841 842	81.	Bosworth ML, Ayoubkhani D, Nafilyan V, Foubert J, Glickman M, Davey C, et al. Deaths involving COVID-19 by self-reported disability status during the first two waves of the COVID-19 pandemic in England: a retrospective, population-based cohort study. Lancet Public Health. 2021 Nov 1;6(11):e817–25.
843 844 845	82.	Shakespeare T, Watson N, Brunner R, Cullingworth J, Hameed S, Scherer N, et al. Disabled people in Britain and the impact of the COVID-19 pandemic. Soc Policy Adm. 2022 Jan 1;56(1):103–17.
846 847 848	83.	Danos C, Heydt Hannah Kuper London P, Burbach M, Rotenberg S, Seghers F, Miner E, et al. Reimagining health systems that expect, accept and connect 1 billion people with disabilities. 2022 Oct.
849 850	84.	Kuper, Hannah; Heydt P. The Missing Billion: access to health services for 1 billion people with disabilities. London; 2019.
851 852 853	85.	lezzoni LI, Rao SR, Ressalam J, Bolcic-Jankovic D, Agaronnik ND, Donelan K, et al. Physicians' perceptions of people with disability and their health care. Health Aff. 2021 Feb 1;40(2):297–306.

854 855	86.	Lagu T, Haywood C, Reimold K, DeJong C, Walker Sterling R, Iezzoni LI. 'I Am Not The Doctor For You': Physicians' Attitudes About Caring For People With Disabilities.
856 857	87.	https://doi.org/101377/hlthaff202200475. 2022 Oct 3;41(10):1387–95. Edwards DJ, Sakellariou D, Anstey S. Barriers to, and facilitators of, access to cancer
858 859		services and experiences of cancer care for adults with a physical disability: A mixed methods systematic review. Disabil Health J. 2020 Jan 1;13(1).
860 861 862	88.	Schwartz JK, Unni E. Inclusion of People with Disabilities in Research to Improve Medication Adherence: A Systematic Review. Patient Prefer Adherence. 2021;15:1671.
863 864	89.	Younossi Alexandria, Sanhai W, Shah S, Chang C. Enhancing diversity in clinical trials Deloitte Insights.
865 866 867 868	90.	Meeting report: summary of Day 2 of the 2021 ISMPP European Meeting [Internet]. [cited 2022 Nov 1]. Available from: https://thepublicationplan.com/2021/02/10/meeting-report-summary-of-day-2-of-the-2021-ismpp-european-meeting/
869 870 871 872	91.	Employing disabled people and people with health conditions - GOV.UK [Internet]. [cited 2022 Nov 1]. Available from: https://www.gov.uk/government/publications/employing-disabled-people-and-people-with-health-conditions/employing-disabled-people-and-people-with-health-conditions
873 874 875 876	92.	Agaronnik N, Campbell EG, Ressalam J, Iezzoni LI. Communicating with Patients with Disability: Perspectives of Practicing Physicians. J Gen Intern Med [Internet]. 2019 Jul 15 [cited 2023 Jul 23];34(7):1139. Available from: /pmc/articles/PMC6614249/
877 878 879	93.	Agaronnik ND, El-Jawahri A, Lindvall C, lezzoni LI. Exploring the Process of Cancer Care for Patients With Pre-Existing Mobility Disability. JCO Oncol Pract. 2021 Jan;17(1):e53–61.
880 881 882	94.	Marlow NM, Samuels SK, Jo A, Mainous AG. Patient-provider communication quality for persons with disabilities: A cross-sectional analysis of the Health Information National Trends Survey. Disabil Health J. 2019 Oct 1;12(4):732–7.
000		

Cancer care for people with disabilities

medF (wh



2023. The copyright holder for this preprint ense to display the preprint in perpetuity. se .